Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib

References

• JungTCatalgolBGruneTThe proteasomal systemMol Aspects Med200930419129619371762
   PubMed Web of Science ®Google Scholar
• RablJSmithDMYuYChangS-CGoldbergALChengYMechanism of gate opening in the 20S proteasome by the proteasomal ATPasesMol Cell200830336036818471981
   PubMed Web of Science ®Google Scholar
• LiuC-WLiXThompsonDATP binding and ATP hydrolysis play distinct roles in the function of 26S proteasomeMol Cell2006241395017018291
   PubMed Web of Science ®Google Scholar
• BraunBCGlickmanMKraftRThe base of the proteasome regulatory particle exhibits chaperone-like activityNat Cell Biol19991422122610559920
   PubMed Web of Science ®Google Scholar
• OrlowskiMWilkSCatalytic activities of the 20S proteasome: a multi-catalytic proteinase complexArch Biochem Biophys2000383111611097171
   PubMed Web of Science ®Google Scholar
• KeithDWUbiquitination and deubiquitination: targeting of proteins for degradation by the proteasomeSemin Cell Dev Biol200011314114810906270
   PubMed Web of Science ®Google Scholar
• DorseyBDIqbalMChatterjeeSDiscovery of a potent, selective, and orally Active proteasome inhibitor for the treatment of cancerJ Med Chem20085141068107218247547
   PubMed Web of Science ®Google Scholar
• KisselevA FCallardAGoldbergALImportance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrateJ Biol Chem2006281138582859016455650
   PubMed Web of Science ®Google Scholar
• GriffnTANandiDCruzMImmunoproteasome assembly: cooperative incorporation of interferon γ (IFN-γ)–inducible subunitsJ Exp Med19981871971049419215
   PubMed Web of Science ®Google Scholar
• DickLRFlemingPEBuilding on bortezomib: second-generation proteasome inhibitors as anti-cancer therapyDrug Discov Today2010155–624324920116451
   PubMed Web of Science ®Google Scholar
• KaneRCFarrellATSridharaRPazdurRUnited States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapyClin Cancer Res200612102955296016707588
   PubMed Web of Science ®Google Scholar
• RichardsonPGWellerELonialSLenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaBlood2010116567968620385792
   PubMed Web of Science ®Google Scholar
• CavoMTacchettiPPatriarcaFBortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised Phase 3 studyLancet201037697582075208521146205
   PubMed Web of Science ®Google Scholar
• NookaAKKaufmanJLBeheraMThe improved efficacy of bortezomib containing induction regimens (BCIR) versus nonbortezomib containing induction regimens (NBCIR) in transplant-eligible patients with multiple myeloma (MM): meta-analysis of Phase III randomized controlled trials (RCTs)ASH Annual Meeting Abstracts2011118213994
   Google Scholar
• BringhenSLaroccaARossiDEfficacy and safety of once-weekly bortezomib in multiple myeloma patientsBlood2010116234745475320807892
   PubMed Web of Science ®Google Scholar
• ArgyriouAAIconomouGKalofonosH PBortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literatureBlood200811251593159918574024
   PubMed Web of Science ®Google Scholar
• WindebankAJGrisoldWChemotherapy-induced neuropathyJ Peripher Nerv Syst2008131274618346229
   PubMed Web of Science ®Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, Phase 3, non-inferiority studyLancet Oncol201112543144021507715
   PubMed Web of Science ®Google Scholar
• OerlemansRFrankeNEAssarafYGMolecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 proteinBlood200811262489249918565852
   PubMed Web of Science ®Google Scholar
• KumarSRajkumarS VMany facets of bortezomib resistance/ susceptibilityBlood200811262177217818779399
   PubMed Web of Science ®Google Scholar
• KuppermanELeeECCaoYEvaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancerCancer Res20107051970198020160034
   PubMed Web of Science ®Google Scholar
• RichardsonPGBazRWangLInvestigational agent MLN9708, an oral proteasome inhibitor in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a Phase 1 dose-escalation studyASH Annual Meeting Abstracts201111821301
   Google Scholar
• KumarSBensingerWIReederCBWeekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: results from a Phase 1 dose-escalation studyASH Annual Meeting Abstracts201111821816
   Google Scholar
• BerdejaJGRichardsonPGLonialSPhase 1/2 study of oral MLN9708, a novel, investigational proteasome inhibitor in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM)ASH Annual Meeting Abstracts201111821479
   Google Scholar
• DurieBGMHarousseauJLMiguelJSInternational uniform response criteria for multiple myelomaLeukemia20062091467147316855634
   PubMed Web of Science ®Google Scholar
• SanchezELiMSteinbergJAOral dosing of the novel proteasome inhibitor CEP-18770 shows marked anti-myeloma effects in SCID-Hu models of multiple myelomaASH Annual Meeting Abstracts2009114221840
   Google Scholar
• PivaRRuggeriBWilliamsMCEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomibBlood200811152765277518057228
   PubMed Web of Science ®Google Scholar
• NIHPhase I study of the proteosome inhibitor CEP 18770 in patients with solid tumours or non-Hodgkin’s lymphomasClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2007 Available from: http://clinicaltrials.gov/show/NCT00572637Accessed February 26, 2012
   Google Scholar
• NIHStudy to determine the maximum tolerated dose and evaluate the efficacy and safety of CEP-18770 in patients with relapsed multiple myeloma refractory to the most recent therapyClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 Available from: http://clinicaltrials.gov/show/NCT01023880Accessed February 26, 2012
   Google Scholar
• NIHCEP-18770 in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myelomaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/show/NCT01348919Accessed February 26, 2012
   Google Scholar
• SanchezENicholsCMLamACEfficacy and tolerability of CEP-18770 in combination with dexamethasone and lenalidomide using a SCID-Hu model of multiple myeloma (MM). ASH Annual Meeting AbstractsNovember 182011118212946
   Google Scholar
• ChauhanDHideshimaTAndersonKCA novel proteasome inhibitor NPI-0052 as an anticancer therapyBr J Cancer20069596196517047643
   PubMed Web of Science ®Google Scholar
• SinghAVLloydGKPalladinoMAChauhanDAndersonKCPharmacodynamic and efficacy studies of a novel proteasome inhibitor NPI-0052 in human plasmacytoma Xenograft Mouse ModelASH Annual Meeting Abstracts2008112113665
   Google Scholar
• ChauhanDCatleyLLiGA novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibCancer Cell20058540741916286248
   PubMed Web of Science ®Google Scholar
• RichardsonPHofmeisterCJakubowiakAPhase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (MM)ASH Annual Meeting Abstracts200911422431
   Google Scholar
• ChauhanDSinghAVCiccarelliBRichardsonPGPalladinoMAAndersonKCCombination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myelomaBlood2010115483484519965674
   PubMed Web of Science ®Google Scholar
• NIHPhase 1 clinical trial of NPI-0052 in patients with advanced solid tumor malignancies or refractory lymphomaClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2006 Available from: http://clinicaltrials.gov/show/NCT00396864Accessed February 26, 2012
   Google Scholar
• NIHPhase 1 clinical trial of NPI-0052 in patients with relapsed or relapsed/refractory multiple myelomaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2007 Available from: http://clinicaltrials.gov/show/NCT00461045Accessed February 26, 2012
   Google Scholar
• NIHProteasome inhibitor NPI-0052 and vorinostat in patients with non-small cell lung cancer, pancreatic cancer, melanoma or lymphomaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2008 Available from: http://clinicaltrials.gov/show/NCT00667082Accessed February 26, 2012
   Google Scholar
• ChauhanDSinghAVAujayMA novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myelomaBlood2010116234906491520805366
   PubMed Web of Science ®Google Scholar
• PapadopoulosKMendelsonDTolcherAA Phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumorsJ Clin Oncol2011Suppl 29Abstr 3075
   Web of Science ®Google Scholar
• NIHOpen-label study of the safety and activity of ONX 0912 in patients with hematological malignanciesClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Avilable from: http://clinicaltrials.gov/show/NCT01416428Accessed February 27, 2012
   Google Scholar
• ElofssonMSplittgerberUMyungJMohanRCrewsCMTowards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α′, β′-epoxyketonesChemistry and Biology199961181182210574782
   PubMedGoogle Scholar
• DikicICrosettoNCalatroniSBernasconiPTargeting ubiquitin in cancersEur J Cancer200642183095310217084074
   PubMed Web of Science ®Google Scholar
• Arastu-KapurSBallAJAnderlJLBennettMKKirkCJNeurodegeneration induced by bortezomib exposure in vitro occurs via proteasome independent mechanismsASH Annual Meeting Abstracts2009114222859
   Google Scholar
• BoldenJEPeartMJJohnstoneRWAnticancer activities of histone deacetylase inhibitorsNat Rev Drug Discov20065976978416955068
   PubMed Web of Science ®Google Scholar
• FuchsOProvaznikovaDMarinovIKuzelovaKSpickaIAntiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cellsCardiovasc Hematol Disord Drug Targets200991627719275578
   PubMedGoogle Scholar
• HideshimaTRichardsonPGAndersonKCMechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myelomaMol Cancer Ther201110112034204222072815
   PubMed Web of Science ®Google Scholar
• MtsiadesCSMitsiadesNSMcMullanCJTranscriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implicationsProc Natl Acad Sci U S A2004101254054514695887
   PubMed Web of Science ®Google Scholar
• ZhangQLWangLZhangYWThe proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/ lymphoma cells apoptosisLeukemia20092381507151419282831
   PubMed Web of Science ®Google Scholar
• BadrosABurgerAMPhilipSPhase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myelomaClin Cancer Res200915165250525719671864
   PubMed Web of Science ®Google Scholar
• RaoRFiskusWYangYCo-treatment with panobinostat enhances bortezomib-induced unfolded protein response, endoplasmic reticulum stress and apoptosis of human mantle cell lymphoma cellsASH Annual Meeting Abstracts200811211887
   Google Scholar
• DasmahapatraGLemberskyDSonMPCarfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivoMol Cancer Ther20111091686169721750224
   PubMed Web of Science ®Google Scholar
• DasmahapatraGLemberskyDKramerLThe pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivoBlood2010115224478448720233973
   PubMed Web of Science ®Google Scholar
• RaoRFiskusWBalusuRTreatment with histone deacetylase 6-specific inhibitor WT-161 disrupts hsp90 function, abrogates aggresome formation and sensitizes human mantle cell lymphoma cells to lethal ER stress induced by proteasome inhibitor carfilzomibASH Annual Meeting Abstracts2010116212856
   Google Scholar
• NIHStudy of carfilzomib and vorinostat for relapsed or refractory lymphomaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/show/NCT01276717Accessed February 27, 2012
   Google Scholar
• NIHA study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in relapsed and/or refractory multiple myeloma (QUAD)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/show/NCT01297764Accessed February 27, 2012
   Google Scholar
• NIHCarfilzomib plus panobinostat in relapsed/refractory multiple myeloma (MM)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/show/NCT01301807Accessed February 27, 2012
   Google Scholar
• NIHStudy of the combination of panobinostat and carfilzomib in patients qith relapsed/refractory multiple myelomaClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/show/NCT01496118Accessed February 27, 2012
   Google Scholar
• StapnesCDøskelandAPHatfeldKThe proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cellsBr J Haematol2007136681482817341267
   PubMed Web of Science ®Google Scholar
• NiewerthDFrankeNJansenGSensitivity of pediatric acute leukemia cells to bortezomib and epoxyketone-based proteasome inhibitors: correlations with proteasome subunit expressionASH Annual Meeting Abstracts2011118211513
   Google Scholar
• GuptaSVHertleinEKWoyachJAThe novel proteasome inhibitor carfilzomib functions independently of p53 to induce potent cytotoxicity in primary chronic lymphocytic leukemia cells and a defective NF-{kappa}B responseASH Annual Meeting Abstracts2011118213510
   Google Scholar
• ZhangLQianJOuZCarfilzomib, an irreversible proteasome inhibitor induces long-term growth inhibition of mantle cell lymphoma in vivoASH Annual Meeting Abstracts2011118213740
   Google Scholar
• GuJHernandez-IlizaliturriFJKaufmanGPMavisCCzuczmanMSCarfilzomib (CFZ): a novel proteasome inhibitor that induces cell cycle arrest and cell death in rituximab-chemotherapy resistant lymphoma and potentiates the anti-tumor activity of chemotherapeutic agentsASH Annual Meeting Abstracts2010116214908
   Google Scholar
• GuJCzuczmanNMKaufmanGPMavisCHernandez-IlizaliturriFJCzuczmanMSThe novel proteasome inhibitor carfilzomib (CFZ) potentiates the anti-tumor activity of chemotherapeutic agents in rituximab-chemotherapy resistant lymphoma through inducing G2/M cell cycle arrest and cell deathASH Annual Meeting Abstracts2011118214970
   Google Scholar
• PhamLVTamayoATLiCLeeJFayadLFordRJChemo-resistance in diffuse large cell lymphoma: novel drug combinations targeting NFAT/NF-Kb growth/survival/chemo-resistance signaling pathways in validated novel experimental systemsASH Annual Meeting Abstracts2011118211428
   Google Scholar
• SaccoAAujayMMorganBCarfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom’s macroglobulinemiaClin Cancer Res20111771753176421355079
   PubMed Web of Science ®Google Scholar
• ZhouH-JAujayMABennettMKDesign and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)J Med Chem20095293028303819348473
   PubMed Web of Science ®Google Scholar
• Arastu-KapurSAnderlJLKrausMNonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse eventsClin Cancer Res20111792734274321364033
   PubMed Web of Science ®Google Scholar
• KuhnDJChenQVoorheesPMPotent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myelomaBlood200711093281329017591945
   PubMed Web of Science ®Google Scholar
• DemoSDKirkCJAujayMAAntitumora of PR-171, a novel irreversible inhibitor of the proteasomeCancer Res200767136383639117616698
   PubMed Web of Science ®Google Scholar
• BerkersCRVerdoesMLichtmanEActivity probe for in vivo profling of the specificity of proteasome inhibitor bortezomibNat Meth200525357362
   Web of Science ®Google Scholar
• KrausMFloreaBBaderJSelective inhibition of the proteasome’s {beta}2 catalytic subunit alone does not induce cytotoxicity, but resen-sitizes bortezomib-refractory myeloma cells for bortezomib treatmentASH Annual Meeting Abstracts2011118212915
   Google Scholar
• ParlatiFLeeSJAujayMCarfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasomeBlood2009114163439344719671918
   PubMed Web of Science ®Google Scholar
• LeeSJWooTMArastu-KapurSWongAFRenauTEKirkCJPotent inhibition of multiple proteasome subunits by carfilzomib in multiple myeloma and solid tumor patientsASH Annual Meeting Abstracts2011118215068
   Google Scholar
• PapadopoulosKPLeePSinghalSA phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56 mg/m2 expansion cohort of PX-171-007ASH Annual Meeting Abstracts2011118212930
   Google Scholar
• YangJWangZFangYPharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in ratsDrug Metab Dispos201139101873188221752943
   PubMed Web of Science ®Google Scholar
• PapadopoulosKMendelsonDTolcherAA Phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumorsJ Clin Oncol2011Suppl 29Abstr 3075
   Web of Science ®Google Scholar
• O’ConnorOAStewartAKValloneMA Phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignanciesClin Cancer Res200915227085709119903785
   PubMed Web of Science ®Google Scholar
• OrlowskiRZStinchcombeTEMitchellBSPhase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesJ Clin Oncol200220224420442712431963
   PubMed Web of Science ®Google Scholar
• LonialSWallerEKRichardsonPGRisk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaBlood2005106123777378416099887
   PubMed Web of Science ®Google Scholar
• AlsinaMTrudelSValloneMMolineauxCKunkelLGoyAPhase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignanciesASH Annual Meeting Abstracts200711011411
   Google Scholar
• JagannathSVijRStewartKFinal results of PX-171-003-A0, part 1 of an open-label, single-arm, Phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)J Clin Oncol200927Suppl 15sAbstr 8504
   Google Scholar
• VijRKaufmanJLJakubowiakAJFinal results from the bortezomib-naive group of PX-171-004, a Phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory MMASH Annual Meeting Abstracts201111821813
   Google Scholar
• SiegelDWangLOrlowskiRZPX-171-004, An ongoing open-label, Phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohortASH Annual Meeting Abstracts200911422303
   Google Scholar
• VijRSiegelDKaufmanJResults of an ongoing open-label, Phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM)J Clin Oncol201028Suppl 15sAbstr 8000
   Google Scholar
• BadrosAVijRMartinTPhase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiencyJ Clin Oncol201028Suppl 15sAbstr 8128
   Web of Science ®Google Scholar
• WangMBensingerWMartinTInterim results from PX-171-006, a Phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM)J Clin Oncol2011Suppl 29Abstr 8025
   Web of Science ®Google Scholar
• MoreauPPalumboAStewartAA randomized, multicenter, Phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM)J Clin Oncol2011Suppl 29abstr TPS225
   Web of Science ®Google Scholar
• JakubowiakAJDytfeldDJagannathSFinal results of a frontline phase 1/2 dtudy of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM)ASH Annual Meeting Abstracts201111821631
   Google Scholar
• SonneveldPHackerEZweegmanSCarfilzomib combined with thalidomide and dexamethasone (CARTHADEX) as induction treatment prior to high-dose melphalan (HDM) in newly diagnosed patients with multiple myeloma (MM). a trial of the European Myeloma Network EMNASH Annual Meeting Abstracts201111821633
   Google Scholar
• SinghalSSiegelDSMartinTIntegrated safety from Phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysisASH Annual Meeting Abstracts2011118211876
   Google Scholar
• NIHA study of carfilzomib maintenance therapy in subjects previously enrolled in carfilzomib treatment protocolsClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2009 Available from: http://clinicaltrials.gov/show/NCT00884312Accessed February 27, 2012
   Google Scholar
• MartinTSinghalSBVijRBaseline peripheral neuropathy does not impact the efficacy and tolerability of the novel proteasome inhibitor carfilzomib (CFZ): results of a subset analysis of a Phase 2 trial in patients with relapsed and refractory multiple myeloma (R/R MM)ASH Annual Meeting Abstracts2010116213031
   Google Scholar
• JakubowaikAJSiegelDSSinghalSUnfavorable cytogenetic characteristics do not adversely impact response rates in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib on the 003 (A1) studyASH Annual Meeting Abstracts2011118211875
   Google Scholar
• BadrosAZVijRMartinTPhase I study of carfilzomib in patients (Pts) with relapsed and refractory multiple myeloma (MM) and varying degrees of renal insufficiencyASH Annual Meeting Abstracts2009114223877
   Google Scholar
• SquiffetPMichielsSSiegelDSVijRRoSBuyseMEMultivariate modelling reveals evidence of a dose-response relationship in Phase 2 studies of single-agent carfilzomibASH Annual Meeting Abstracts2011118211877
   Google Scholar
• WangLSiegelDSJakubowiakAJThe speed of response to singleagent carfilzomib in patients with relapsed and/or refractory multiple myeloma: an exploratory analysis of results from 2 multicenter Phase 2 clinical yrialsASH Annual Meeting Abstracts2011118213969
   Google Scholar
• JagannathSVijRKaufmanJLLong-term treatment and tolerability of the novel proteasome inhibitor carfilzomib (CFZ) in patients with relapsed and/or refractory multiple myeloma (R/R MM)ASH Annual Meeting Abstracts2010116211953
   Google Scholar
• SiegelDMartinTWangMPX-171-003-A1, an open-label, single-arm, Phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): long-term follow-up and subgroup analysisJ Clin Oncol2011Suppl 29Abstr 8027
   Web of Science ®Google Scholar
• NIHCarfilzomib in patients with relapsed acute myeloid or acute lymphoblastic leukemia (AML ALL)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 Available from: http:/clinicaltrials.gov/show/NCT01137747Accessed February 27, 2012
   Google Scholar
• NIHStudy of carfilzomib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) or prolymphocytic leukemia (PLL)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 Available from: http:/clinicaltrials.gov/show/NCT01212380Accessed February 27, 2012
   Google Scholar
• NIHCarfilzomib in treating patients with relapsed or refractory T-cell lymphomaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http:/clinicaltrials.gov/show/NCT01336920Accessed February 26, 2012
   Google Scholar
• NIHPhase 1b multicenter study of carfilzomib with lenalidomide and dexamethasone in relapsed multiple myelomaClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2008 Available from http:/clinicaltrials.gov/show/NCT00603447Accessed February 27, 2012
   Google Scholar
• NIHA safety study of carfilzomib and pomalidomide with dexamethasone in patients with relapsed or refractory multiple myelomaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/show/NCT01464034Accessed February 27, 2012
   Google Scholar
• NIHStudy of carfilzomib for multiple myeloma patients who are relapsed/refractory to bortezomib-containing treatmentsClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltri-als.gov/show/NCT01365559Accessed February 27, 2012
   Google Scholar
• NIHTrial of carfilzomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma (CARMYSAP)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 Available from: http://clinicaltrials.gov/show/NCT01279694Accessed February 27, 2012
   Google Scholar
• NIHCarfilzomib and pegylated liposomal doxorubicin hydrochloride in treating patients with relapsed or refractory multiple myelomaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/show/NCT01246063Accessed February 27, 2012
   Google Scholar
• NIHArry-520 + carfilzomib for multiple myeloma (MM)Clini-calTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2012 Available from: http://clinicaltrials.gov/show/NCT01372540Accessed February 27, 2012
   Google Scholar
• NIHCyclophosphamide, carfilzomib, thalidomide, and dexamethasone in treating patients with newly diagnosed active multiple myelomaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 Available from: http://clinicaltrials.gov/show/NCT01057225Accessed February 27, 2012
   Google Scholar
• NIHCarfilzomib and lenalidomide with dexamethasone combination in newly diagnosed, previously untreated multiple myelomaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2009 Available from: http://clinicaltrials.gov/show/NCT01029054Accessed February 27, 2012
   Google Scholar
• NIHCarfilzomib, rituximab and dexamethasone in Waldenstrom’s macroglobulinemia (CaRD)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/show/NCT01470196Accessed February 27, 2012
   Google Scholar
• NIHInfusional carfilzomib in patients with relapsed or refractory multiple myelomaClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/show/NCT01351623Accessed February 27, 2012
   Google Scholar
• NIHCarfilzomib, cyclophosphamide and dexamethasone in newly diagnosed multiple myeloma patients (CCD)ClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/show/NCT01346787Accessed February 27, 2012
   Google Scholar
• NIHCarfilzomib, lenalidomide, and dexamethasone in new multiple myeloma patientsClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://clinicaltrials.gov/show/NCT01402284Accessed February 27, 2012
   Google Scholar
• NIHPhase 3 study comparing carfilzomib, lenalidomide, and dexamethasone (CRd) versus lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myelomaClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 Available from: http://clinicaltrials.gov/show/NCT01080391Accessed February 27, 2012
   Google Scholar
• NIHA study of carfilzomib vs best supportive care in subjects with relapsed and refractory multiple myeloma (FOCUS)ClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 Avilable from: http://clinicaltrials.gov/show/NCT01302392Accessed February 27, 2012
   Google Scholar